Giuseppe Masucci

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

*/Giuseppe Masucci: /*Anknuten forskare vid institutionen för
onkologi-patologi. Docent och överläkare vid Onkologiska kliniken,
Karolinska Universitetssjukhuset.
* Född 1951, specialist i onkologi.
* Har läkarexamen från universitetet i Ferrara, Italien.
* Är knuten till Radiumhemmet i Stockholm sedan 1979.
* Medverkar i Socialstyrelsens Kunskapscentrum för strålningsmedicin vid
katastrofer (KcRN) som är en beredskapsfunktion vid Centrum för
strålningsmedicin.
* Medlem i Socialstyrelsens medicinska expertgrupp för radiologiska och
nukleära händelser (RN-MeG).

Forskningsbeskrivning

Giuseppe Masuccis forskning är inriktad på immunoterapi och därmed
relaterade prognosfaktorer som kan utnyttjas för ”personaliserad”
(individrelaterad) cancermedicin. Hans grupp har fastställt att patientens
vävnadstyp (HLA-antigen) har stor betydelse för den som utvecklat en malign
tumörsjukdom. Gruppen har på senare år särskilt fokuserat på frekvensen
av HLA-A2-allelen i Skandinavien
denna genvariant är korrelerad med
dödligheten i äggstocks- och prostatacancer.
Giuseppe Masucci utvecklar också kombinationsbehandlingar med så kallad
stereotaktisk ablativ radioterapi (SABR), som ger höga välavgränsade
stråldoser till små tumörer, följd av immunterapi

Artiklar

Article: CANCERS. 2023;15(2):418

Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer.

Mlecnik B; Lugli A; Bindea G; Marliot F; Bifulco C; Lee J-KJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; Vliet SVL-V; Knijn N; Mușină A-M; Scripcariu D-V; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Patel P; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
Article: CANCERS. 2022;14(18):4346

Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study.

Mlecnik B; Torigoe T; Bindea G; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Hirohashi Y; Furuhata T; Takemasa I; Patel P; Vora H; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Yoshino T; Taniguchi H; Bifulco C; Lugli A; Lee J-KJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson E; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Marliot F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; Van de Water C; van Lent-van Vliet S; Knijn N; Mușină A-M; Scripcariu D-V; Marincola FM; Ascierto PA; Fox BA; Pagès F; Kawakami Y; Galon J
Article: CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 2022;36:91-98

Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases.

Lindberg S; Onjukka E; Wersäll P; Staff C; Lewensohn R; Masucci G; Lindberg K
Article: CANCERS. 2021;13(16):4164

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.

Madonna G; Masucci GV; Capone M; Mallardo D; Grimaldi AM; Simeone E; Vanella V; Festino L; Palla M; Scarpato L; Tuffanelli M; D'angelo G; Villabona L; Krakowski I; Eriksson H; Simao F; Lewensohn R; Ascierto PA
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2021;19(1):132

Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.

Isgrò MA; Vitale MG; Celentano E; Nocerino F; Porciello G; Curvietto M; Mallardo D; Montagnese C; Russo L; Zanaletti N; Avallone A; Pensabene M; De Laurentiis M; Centonze S; Pignata S; Cannella L; Morabito A; Caponigro F; Botti G; Masucci GV; Giannarelli D; Cavalcanti E; Ascierto PA
Article: CANCERS. 2021;13(2):E265-265

Sex Differences in Overall Survival and the Effect of Radiotherapy in Merkel Cell Carcinoma-A Retrospective Analysis of a Swedish Cohort.

Björn Andtback H; Björnhagen-Säfwenberg V; Shi H; Lui W-O; Masucci GV; Villabona L
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(1):105-115

Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting.

Krakowski I; Bottai M; Häbel H; Masucci G; Girnita A; Smedby KE; Eriksson H
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8(2):e001472

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challenges.

Cesano A; Cannarile MA; Gnjatic S; Gomes B; Guinney J; Karanikas V; Karkada M; Kirkwood JM; Kotlan B; Masucci GV; Meeusen E; Monette A; Naing A; Thorsson V; Tschernia N; Wang E; Wells DK; Wyant TL; Rutella S
Article: CANCERS. 2020;12(11):E3238-3238

Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer.

Herrera M; Mezheyeuski A; Villabona L; Corvigno S; Strell C; Klein C; Hölzlwimmer G; Glimelius B; Masucci G; Sjöblom T; Östman A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(31):3638-3651

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.

Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină A-M; Scripcariu D-V; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8(2):e001389

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges.

Rutella S; Cannarile MA; Gnjatic S; Gomes B; Guinney J; Karanikas V; Karkada M; Kirkwood JM; Kotlan B; Masucci GV; Meeusen E; Monette A; Naing A; Thorsson V; Tschernia N; Wang E; Wells DK; Wyant TL; Cesano A
Article: ONCOIMMUNOLOGY. 2020;9(1):1786888

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates.

Pico de Coaña Y; Wolodarski M; van der Haar Àvila I; Nakajima T; Rentouli S; Lundqvist A; Masucci G; Hansson J; Kiessling R
Article: ONCOIMMUNOLOGY. 2020;9(1):1792058

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination.

Lövgren T; Wolodarski M; Wickström S; Edbäck U; Wallin M; Martell E; Markland K; Blomberg P; Nyström M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2019;17(1):234

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).

Ascierto PA; Agarwala SS; Botti G; Budillon A; Davies MA; Dummer R; Ernstoff M; Ferrone S; Formenti S; Gajewski TF; Garbe C; Hamid O; Lo RS; Luke JJ; Michielin O; Palmieri G; Zitvogel L; Marincola FM; Masucci G; Caracò C; Thurin M; Puzanov I
Article: MOLECULAR ONCOLOGY. 2019;13(2):376-391

Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer.

Franzén B; Alexeyenko A; Kamali-Moghaddam M; Hatschek T; Kanter L; Ramqvist T; Kierkegaard J; Masucci G; Auer G; Landegren U; Lewensohn R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2018;16(1):207

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).

Ascierto PA; Puzanov I; Agarwala SS; Bifulco C; Botti G; Caracò C; Ciliberto G; Davies MA; Dummer R; Ferrone S; Gajewski TF; Garbe C; Luke JJ; Marincola FM; Masucci G; Mehnert JM; Mozzillo N; Palmieri G; Postow MA; Schoenberger SP; Wang E; Thurin M
Article: LANCET. 2018;391(10135):2128-2139

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Pagès F; Mlecnik B; Marliot F; Bindea G; Ou F-S; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Mușină A-M; Scripcariu D-V; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
Article: EUROPEAN JOURNAL OF CANCER. 2017;86:115-124

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2017;15(1):212

World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016.

Galon J; Lugli A; Bifulco C; Pages F; Masucci G; Marincola FM; Ascierto PA
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2017;66(10):1333-1344

Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.

Lövgren T; Sarhan D; Truxová I; Choudhary B; Maas R; Melief J; Nyström M; Edbäck U; Vermeij R; Scurti G; Nishimura M; Masucci G; Karlsson-Parra A; Lundqvist A; Adamson L; Kiessling R
Article: ONCOTARGET. 2017;8(13):21539-21553

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.

de Coaña YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nyström M; Edbäck U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14(1):313

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14:273

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.

Galon J; Fox BA; Bifulco CB; Masucci G; Rau T; Botti G; Marincola FM; Ciliberto G; Pages F; Ascierto PA; Capone M
Article: ONCOIMMUNOLOGY. 2016;5(1):e1052213

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis.

Andersson E; Poschke I; Villabona L; Carlson JW; Lundqvist A; Kiessling R; Seliger B; Masucci GV
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2015;13:374

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
Article: TRANSLATIONAL RESEARCH. 2015;166(2):207-217

Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome.

Koelzer VH; Dawson H; Andersson E; Karamitopoulou E; Masucci GV; Lugli A; Zlobec I
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2014;12:277

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Ascierto PA; Grimaldi AM; Anderson AC; Bifulco C; Cochran A; Garbe C; Eggermont AM; Faries M; Ferrone S; Gershenwald JE; Gajewski TF; Halaban R; Hodi FS; Kefford R; Kirkwood JM; Larkin J; Leachman S; Maio M; Marais R; Masucci G; Melero I; Palmieri G; Puzanov I; Ribas A; Saenger Y; Schilling B; Seliger B; Stroncek D; Sullivan R; Testori A; Wang E; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2014;63(10):1061-1071

A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma.

Poschke I; Lövgren T; Adamson L; Nyström M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R
Article: MODERN PATHOLOGY. 2014;27(9):1296-1305

A novel approach for HLA-A typing in formalin-fixed paraffin-embedded-derived DNA.

Villabona L; Leon Rodriguez DA; Andersson EK; Seliger B; Dalianis T; Masucci GV
Article: ANTICANCER RESEARCH. 2014;34(5):2369-2375

HLA-A*02 in relation to outcome in human papillomavirus positive tonsillar and base of tongue cancer.

Tertipis N; Villabona L; Nordfors C; Näsman A; Ramqvist T; Vlastos A; Masucci G; Dalianis T
Article: METHODS IN MOLECULAR BIOLOGY. 2014;1102:353-366

Genotyping of human leukocyte antigen (HLA) ancestral haplotypes as prognostic marker in cancer using PCR analysis.

Villabona L; Andersson E; Marchesi M; Masucci GV
Article: CANCER IMMUNOLOGY RESEARCH. 2013;1(3):158-162

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

Pico de Coaña Y; Poschke I; Gentilcore G; Mao Y; Nyström M; Hansson J; Masucci GV; Kiessling R
Article: CANCER RESEARCH. 2013;73(13):3877-3887

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

Mao Y; Poschke I; Wennerberg E; Pico de Coaña Y; Egyhazi Brage S; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: PLOS ONE. 2013;8(10):e77025

HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome.

Näsman A; Andersson E; Marklund L; Tertipis N; Hammarstedt-Nordenvall L; Attner P; Nyberg T; Masucci GV; Munck-Wikland E; Ramqvist T; Dalianis T
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(8):1243-1253

Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.

Andersson E; Villabona L; Bergfeldt K; Carlson JW; Ferrone S; Kiessling R; Seliger B; Masucci GV
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(6):827-838

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.

Poschke I; Mao Y; Adamson L; Salazar-Onfray F; Masucci G; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2011;9:214

Defining the critical hurdles in cancer immunotherapy.

Fox BA; Schendel DJ; Butterfield LH; Aamdal S; Allison JP; Ascierto PA; Atkins MB; Bartunkova J; Bergmann L; Berinstein N; Bonorino CC; Borden E; Bramson JL; Britten CM; Cao X; Carson WE; Chang AE; Characiejus D; Choudhury AR; Coukos G; de Gruijl T; Dillman RO; Dolstra H; Dranoff G; Durrant LG; Finke JH; Galon J; Gollob JA; Gouttefangeas C; Grizzi F; Guida M; Håkansson L; Hege K; Herberman RB; Hodi FS; Hoos A; Huber C; Hwu P; Imai K; Jaffee EM; Janetzki S; June CH; Kalinski P; Kaufman HL; Kawakami K; Kawakami Y; Keilholtz U; Khleif SN; Kiessling R; Kotlan B; Kroemer G; Lapointe R; Levitsky HI; Lotze MT; Maccalli C; Maio M; Marschner J-P; Mastrangelo MJ; Masucci G; Melero I; Melief C; Murphy WJ; Nelson B; Nicolini A; Nishimura MI; Odunsi K; Ohashi PS; O'Donnell-Tormey J; Old LJ; Ottensmeier C; Papamichail M; Parmiani G; Pawelec G; Proietti E; Qin S; Rees R; Ribas A; Ridolfi R; Ritter G; Rivoltini L; Romero PJ; Salem ML; Scheper RJ; Seliger B; Sharma P; Shiku H; Singh-Jasuja H; Song W; Straten PT; Tahara H; Tian Z; van Der Burg SH; von Hoegen P; Wang E; Welters MJ; Winter H; Withington T; Wolchok JD; Xiao W; Zitvogel L; Zwierzina H; Marincola FM; Gajewski TF; Wigginton JM; Disis ML
Article: LAKARTIDNINGEN. 2011;108(20):1092-1093

[Paradigmatic shift in oncology: individualized melanoma treatment].

Hansson J; Djureen-Mårtenson E; Edvinsson F; Falkenius J; Friesland S; Masucci G; Månsson-Brahme E; Ragnarsson-Olding B; Sjödin H; Wolodarski M; Frohm-Nilsson M; Lapins J
Article: CLINICAL CANCER RESEARCH. 2011;17(10):3064-3076

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Butterfield LH; Palucka AK; Britten CM; Dhodapkar MV; Håkansson L; Janetzki S; Kawakami Y; Kleen T-O; Lee PP; Maccalli C; Maecker HT; Maino VC; Maio M; Malyguine A; Masucci G; Pawelec G; Potter DM; Rivoltini L; Salazar LG; Schendel DJ; Slingluff CL; Song W; Stroncek DF; Tahara H; Thurin M; Trinchieri G; van Der Burg SH; Whiteside TL; Wigginton JM; Marincola F; Khleif S; Fox BA; Disis ML
Article: PHARMACEUTICAL STATISTICS. 2011;10(3):218-226

Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas.

Zohar S; Baldi I; Forni G; Merletti F; Masucci G; Gregori D
Article: CANCER RESEARCH. 2010;70(11):4335-4345

Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

Poschke I; Mougiakakos D; Hansson J; Masucci GV; Kiessling R
Article: CANCER RESEARCH. 2010;70(7):2604-2612

A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins.

Quaglino E; Mastini C; Amici A; Marchini C; Iezzi M; Lanzardo S; De Giovanni C; Montani M; Lollini P-L; Masucci G; Forni G; Cavallo F
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(10):1599-1608

The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma.

Helgadottir H; Andersson E; Villabona L; Kanter L; van der Zanden H; Haasnoot GW; Seliger B; Bergfeldt K; Hansson J; Ragnarsson-Olding B; Kiessling R; Masucci GV
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(7):1085-1094

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.

Johansson CC; Egyházi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Article: HLA. 2007;70(3):205-213

Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer.

Gamzatova Z; Villabona L; van der Zanden H; Haasnoot GW; Andersson E; Kiessling R; Seliger B; Kanter L; Dalianis T; Bergfeldt K; Masucci GV
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2007;56(7):973-984

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients.

Hanson MGV; Ozenci V; Carlsten MCV; Glimelius BL; Frödin J-EA; Masucci G; Malmberg K-J; Kiessling RVR
Article: GYNECOLOGIC ONCOLOGY. 2006;103(1):145-150

Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.

Gamzatova Z; Villabona L; Dahlgren L; Dalianis T; Nillson B; Bergfeldt K; Masucci GV
Article: MELANOMA RESEARCH. 2006;16(4):357-363

Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.

Masucci GV; Månsson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Article: CANCER RESEARCH. 2006;66(12):6387-6394

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.

Norell H; Carlsten M; Ohlum T; Malmberg K-J; Masucci G; Schedvins K; Altermann W; Handke D; Atkins D; Seliger B; Kiessling R
Article: IMMUNOLOGY LETTERS. 2005;100(2):113-119

Effects of human plasma proteins on maturation of monocyte-derived dendritic cells.

Tobiásová-Czetoová Z; Palmborg A; Lundqvist A; Karlsson G; Adamson L; Bartůnková J; Masucci G; Pisa P
Article: MEDICAL ONCOLOGY. 2005;22(3):247-256

Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study.

Masucci G; Broman P; Kelly C; Lindahl S; Malmberg L; Reizenstein J; Alenius M; Lewensohn R
Article: BRITISH JOURNAL OF CANCER. 2004;91(4):688-694

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

Pavlenko M; Roos A-K; Lundqvist A; Palmborg A; Miller AM; Ozenci V; Bergman B; Egevad L; Hellström M; Kiessling R; Masucci G; Wersäll P; Nilsson S; Pisa P
Article: MEDICAL ONCOLOGY. 2004;21(1):49-52

Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates.

De Petris L; Bergfeldt K; Hising C; Lundqvist A; Tholander B; Pisa P; van der Zanden HGM; Masucci G
Article: CYTOTHERAPY. 2004;6(4):363-371

Development of a technology platform for large-scale clinical grade production of DC.

Adamson L; Palmborg A; Svensson A; Lundqvist A; Hansson M; Kiessling R; Masucci G; Mellstedt H; Pisa P
Article: CLINICAL CANCER RESEARCH. 2002;8(6):1772-1778

A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer.

Malmberg K-J; Lenkei R; Petersson M; Ohlum T; Ichihara F; Glimelius B; Frödin J-E; Masucci G; Kiessling R
Article: HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. 2001;23(11):1006-1010

Leakage around voice prosthesis in laryngectomees: treatment with local GM-CSF.

Margolin G; Masucci G; Kuylenstierna R; Björck G; Hertegård S; Karling J
Article: JOURNAL OF IMMUNOLOGY. 2001;167(5):2595-2601

Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation.

Malmberg KJ; Arulampalam V; Ichihara F; Petersson M; Seki K; Andersson T; Lenkei R; Masucci G; Pettersson S; Kiessling R
Article: MEDICAL ONCOLOGY. 2001;18(3):231-235

GM-CSF at relatively high topic concentrations can significantly enhance the healing of surgically induced chronic wounds after radiotherapy.

Fernberg JO; Brosjö O; Friesland S; Masucci G
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;80(2):219-230

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.

Marchand M; van Baren N; Weynants P; Brichard V; Dréno B; Tessier MH; Rankin E; Parmiani G; Arienti F; Humblet Y; Bourlond A; Vanwijck R; Liénard D; Beauduin M; Dietrich PY; Russo V; Kerger J; Masucci G; Jäger E; De Greve J; Atzpodien J; Brasseur F; Coulie PG; van der Bruggen P; Boon T
Article: CANCER RESEARCH. 1997;57(19):4348-4355

Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.

Salazar-Onfray F; Nakazawa T; Chhajlani V; Petersson M; Kärre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R
Article: STEM CELLS AND DEVELOPMENT. 1997;6(3):253-260

Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).

Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
Article: MEDICAL ONCOLOGY. 1996;13(3):149-154

New clinical applications of granulocyte-macrophage colony-stimulating factor.

Masucci G
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1996;26(6):1308-1313

Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity.

Kono K; Salazar-Onfray F; Petersson M; Hansson J; Masucci G; Wasserman K; Nakazawa T; Anderson P; Kiessling R
Article: CANCER RESEARCH, THERAPY AND CONTROL. 1995;4(3):223-229

ANTIBODIES TO EPSTEIN-BARR-VIRUS IN RELATION TO CLINICAL CHARACTERISTICS OF UNTREATED PATIENTS WITH HODGKINS-DISEASE

MERK K; LENNETTE E; HOLM G; JOHANSSON B; MASUCCI G; GRIMFORS G; KLEIN G; BJORKHOLM M
Visa fler

Alla övriga publikationer

Letter: ACTA ONCOLOGICA. 2022;61(7):869-873

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial.

Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersäll P; Edbäck U; Wickström S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzén B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
Review: LAKARTIDNINGEN. 2021;118:21114

[Overview of immune-related side effects from immune checkpoint inhibitors. Part 2: Endocrine, rheumatologic and skin toxicity].

Helgadottir H; Falkenius J; Eriksson H; Girnita A; Sahlberg L; Bensing S; Chatzidionysiou K; Masucci G; Ullenhag G
Corrigendum: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(6):1407

Corrigendum: Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting.

Krakowski I; Bottai M; Habel H; Masucci G; Girnita A; Smedby KE; Eriksson H
Editorial comment: ACTA DERMATO-VENEREOLOGICA. 2020;100(18):adv00334-0

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma.

Eriksson H; Hansson J; Krynitz B; Masucci G; Girnita A; Lapins J; Huen AO; Tawbi HA; Davies MA; Tetzlaff MT; Curry JL
Editorial comment: JOURNAL OF TRANSLATIONAL MEDICINE. 2017;15(1):223

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy.

Masucci GV; Cesano A; Eggermont A; Fox BA; Wang E; Marincola FM; Ciliberto G; Dobbin K; Puzanov I; Taube J; Wargo J; Butterfield LH; Villabona L; Thurin M; Postow MA; Sondel PM; Demaria S; Agarwala S; Ascierto PA
Letter: ANNALS OF ONCOLOGY. 2017;28(7):1672-1673

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.

Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
Review: DRUGS. 2016;76(9):925-945

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
Review: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2016;4:76

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.

Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
Review: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2016;4:77

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.

Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
Editorial comment: LANCET ONCOLOGY. 2015;16(13):1285-1287

PD-L1 expression as a potential predictive biomarker.

Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
Review: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2014;63(9):977-983

Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy.

Pico de Coaña Y; Masucci G; Hansson J; Kiessling R
Review: JOURNAL OF PATHOLOGY. 2014;232(2):199-209

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.

Galon J; Mlecnik B; Bindea G; Angell HK; Berger A; Lagorce C; Lugli A; Zlobec I; Hartmann A; Bifulco C; Nagtegaal ID; Palmqvist R; Masucci GV; Botti G; Tatangelo F; Delrio P; Maio M; Laghi L; Grizzi F; Asslaber M; D'Arrigo C; Vidal-Vanaclocha F; Zavadova E; Chouchane L; Ohashi PS; Hafezi-Bakhtiari S; Wouters BG; Roehrl M; Nguyen L; Kawakami Y; Hazama S; Okuno K; Ogino S; Gibbs P; Waring P; Sato N; Torigoe T; Itoh K; Patel PS; Shukla SN; Wang Y; Kopetz S; Sinicrope FA; Scripcariu V; Ascierto PA; Marincola FM; Fox BA; Pagès F
Corrigendum: CANCER IMMUNOLOGY RESEARCH. 2013;1(6):438

Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid Derived Suppressor Cells as well as Their Arginase1 Production (vol 1, pg 158, 2013)

de Coana YP; Poschke I; Gentilcore G; Mao Y; Nystrom M; Hansson J; Masucci GV; Kiessling R
Review: JOURNAL OF TRANSLATIONAL MEDICINE. 2013;11:247

HLA-dependent tumour development: a role for tumour associate macrophages?

Marchesi M; Andersson E; Villabona L; Seliger B; Lundqvist A; Kiessling R; Masucci GV
Review: JOURNAL OF TRANSLATIONAL MEDICINE. 2012;10:205

Cancer classification using the Immunoscore: a worldwide task force.

Galon J; Pagès F; Marincola FM; Angell HK; Thurin M; Lugli A; Zlobec I; Berger A; Bifulco C; Botti G; Tatangelo F; Britten CM; Kreiter S; Chouchane L; Delrio P; Arndt H; Asslaber M; Maio M; Masucci GV; Mihm M; Vidal-Vanaclocha F; Allison JP; Gnjatic S; Hakansson L; Huber C; Singh-Jasuja H; Ottensmeier C; Zwierzina H; Laghi L; Grizzi F; Ohashi PS; Shaw PA; Clarke BA; Wouters BG; Kawakami Y; Hazama S; Okuno K; Wang E; O'Donnell-Tormey J; Lagorce C; Pawelec G; Nishimura MI; Hawkins R; Lapointe R; Lundqvist A; Khleif SN; Ogino S; Gibbs P; Waring P; Sato N; Torigoe T; Itoh K; Patel PS; Shukla SN; Palmqvist R; Nagtegaal ID; Wang Y; D'Arrigo C; Kopetz S; Sinicrope FA; Trinchieri G; Gajewski TF; Ascierto PA; Fox BA
Editorial comment: JOURNAL OF TRANSLATIONAL MEDICINE. 2012;10:104

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours.

Masucci GV; Wersäll P; Kiessling R; Lundqvist A; Lewensohn R
Review: JOURNAL OF TRANSLATIONAL MEDICINE. 2009;7:45

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Tahara H; Sato M; Thurin M; Wang E; Butterfield LH; Disis ML; Fox BA; Lee PP; Khleif SN; Wigginton JM; Ambs S; Akutsu Y; Chaussabel D; Doki Y; Eremin O; Fridman WH; Hirohashi Y; Imai K; Jacobson J; Jinushi M; Kanamoto A; Kashani-Sabet M; Kato K; Kawakami Y; Kirkwood JM; Kleen TO; Lehmann PV; Liotta L; Lotze MT; Maio M; Malyguine A; Masucci G; Matsubara H; Mayrand-Chung S; Nakamura K; Nishikawa H; Palucka AK; Petricoin EF; Pos Z; Ribas A; Rivoltini L; Sato N; Shiku H; Slingluff CL; Streicher H; Stroncek DF; Takeuchi H; Toyota M; Wada H; Wu X; Wulfkuhle J; Yaguchi T; Zeskind B; Zhao Y; Zocca M-B; Marincola FM
Editorial comment: JOURNAL OF TRANSLATIONAL MEDICINE. 2008;6:81

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

Butterfield LH; Disis ML; Fox BA; Lee PP; Khleif SN; Thurin M; Trinchieri G; Wang E; Wigginton J; Chaussabel D; Coukos G; Dhodapkar M; Håkansson L; Janetzki S; Kleen TO; Kirkwood JM; Maccalli C; Maecker H; Maio M; Malyguine A; Masucci G; Palucka AK; Potter DM; Ribas A; Rivoltini L; Schendel D; Seliger B; Selvan S; Slingluff CL; Stroncek DF; Streicher H; Wu X; Zeskind B; Zhao Y; Zocca M-B; Zwierzina H; Marincola FM
Editorial comment: MEDICAL ONCOLOGY. 2002;19(4):195-196

Dendritic cells highly quoted on immunotherapy stock market.

Masucci G
Editorial comment: MEDICAL ONCOLOGY. 1999;16(1):13-16

Will modern cancer vaccines reach clinical practice?

Masucci G
Review: CRITICAL REVIEWS IN ONCOGENESIS. 1999;10(1-2):83-127

Cells and cytokines in immunotherapy and gene therapy of cancer.

Pawelec G; Rees RC; Kiessling R; Madrigal A; Dodi A; Baxevanis C; Gambacorti-Passerini C; Masucci G; Zeuthen J
Visa fler

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Anställningar

Handledare

Nyheter från KI

Kalenderhändelser från KI